This market research report includes a detailed segmentation of the global non-alcoholic steatohepatitis market by dosage form (solid and liquid) and by route of administration (oral and parenteral). It also outlines the market shares for key regions like the Americas, APAC, and Europe. The leading vendors analyzed in this report are AstraZeneca, Arena Pharmaceuticals, GlaxoSmithKline, Novo Nordisk, Roche, and Vivus.
Technavio’s market research analysts estimate the global NASH market to grow at a CAGR of almost 25% between 2016 and 2020. The high incidence of diabetes and obesity and the lack of effective treatment solutions are the key factors driving this market’s growth. Moreover, the launch of new drugs with a high efficacy rate and safety profile is expected to have a positive impact on the growth of the market. At present, the Americas dominate the global NASH market by accounting for around 60% of the overall market share. The increase in sedentary lifestyles of people and significant unmet medical needs are expected to contribute to the growth of the NASH market in this region.
The new market research report from Technavio presents a breakdown and analysis of the NASH segments by route of administration.
“Numerous organizations, both governmental and non-governmental, are organizing campaigns, summits, seminars, and fundraising events to create awareness about liver diseases. For instance, the American Liver Foundation and the Canadian Liver Foundation celebrate October as Liver Awareness Month to spread awareness about liver cancer, NAFL disease, NASH, and liver cirrhosis in the respective countries. Better awareness leads to more people opting for therapeutic drugs for treatment, thereby boosting their sales,” says Barath Palada, Lead Analyst, Pharma, Technavio Research.
The oral segment dominates the global NASH market as it is the better preferred route of drug ingestion for the treatment of NASH. Medications administered through the oral route ensure a systemic effect, undergo first-pass metabolism and are mostly absorbed by the small intestine. They are administered as tablets, capsules, or oral liquids. Forxiga/Farxiga and Komboglyze are some of the drugs orally administered to people with NASH.
The key vendors in the market include AstraZeneca, Arena Pharmaceuticals, GlaxoSmithKline, Novo Nordisk, Roche, and Vivus. The global non-alcoholic steatohepatitis market is highly competitive owing to the presence of numerous small and large players that operate on a local or global scale. The vendors in this market compete on the basis of price, quality, and innovation. The high level of competition in this market has led to an increase in the number of M&A, wherein smaller entities are being acquired by, or are being merged with, major players.
A more detailed analysis is available on the Technavio report, Global NASH Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
